Eisai Licenses Kissei's Glufast For Southeast Asian Market
This article was originally published in PharmAsia News
Executive Summary
Eisai has signed a licensing agreement with Japanese pharmaceutical firm Kissei to develop and commercialize Kissei's Glufast (mitiglinide calcium hydrate) in 10 Southeast Asian countries, the companies announced June 12
You may also be interested in...
Phase III Results Buoy Watson’s Benign Prostatic Hyperplasia Candidate
Silodosin would take on GSK’s Avodart and Pfizer’s Cardura XL.
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).